Serica

Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Thursday, August 4, 2022
FDA, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, David Berry (inventor), Canaccord Genuity, Hematopoietic stem cell transplantation, Patient, Company, Nasdaq, Tissue, FDA, Graft-versus-host disease, Research, Therapy, Conference, Ulcerative colitis, Bloodstream infections, Serica, Pharmaceutical industry

(Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m.

Key Points: 
  • (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m.
  • An audio webcast of the presentation will be available under the Investors and News section of Seres website.
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.
  • The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 3, 2022
Health, Other Health, Other Science, General Health, Research, Science, Janus, Pharmacology, Nasdaq, David Berry (inventor), DDW, CDI, Conference, File, ASCO, COVID-19, Research, Therapy, Graft-versus-host disease, NEJM, GI, U.S. Securities and Exchange Commission, Fatty acid, Radiation, The New England Journal of Medicine, Society, American Society of Clinical Oncology, Patient, Trial of the century, Flagship Pioneering, Mucositis, Diagnosis, Ulcerative colitis, Cirrhosis, Pharmacokinetics, PCR, Death, Infection, Growth, Safety, Program, Private Securities Litigation Reform Act, Clostridioides difficile infection, Adult, Tissue, Investment, Company, Incidence, Hematopoietic stem cell transplantation, Recurrence, SEC, Variometer, Security (finance), Disease, Leadership, BLA, FDA, Bloodstream infections, Pharmaceutical industry, Medical device, Vaccine, EU, Serica, UC

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2022 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported second quarter 2022 financial results and provided business updates.
  • The results were consistent with the previous ECOSPOR III results and were consistent across key subpopulations, including in individuals with a first recurrence of CDI.
  • Research and development expenses for the second quarter of 2022 were $43.9 million, compared with $36.0 million for the same period in 2021.
  • Seres ended the second quarter of 2022 with approximately $195.8 million in cash, cash equivalents and investments.

Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022

Retrieved on: 
Thursday, July 28, 2022
Health, FDA, Stem Cells, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Graft-versus-host disease, Tissue, Bloodstream infections, Ulcerative colitis, Research, David Berry (inventor), Therapy, FDA, Company, Patient, Nasdaq, Hematopoietic stem cell transplantation, Pharmaceutical industry, Serica

(Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m.

Key Points: 
  • (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m.
  • ET to discuss second quarter 2022 results and provide a general business update.
  • To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 3171491.
  • To join the live webcast, please visit the Investors and News section of the Seres website at www.serestherapeutics.com .

Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock

Retrieved on: 
Thursday, June 30, 2022
Health, FDA, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Janus, Flagship Pioneering, David Berry (inventor), SEC filing, COVID-19, Sale, U.S. Securities and Exchange Commission, Telephone, J.P. Morgan & Co., Form, Therapy, LLC, Private Securities Litigation Reform Act, Nasdaq, SEC, Broadridge Financial Solutions, Security (finance), Pharmaceutical industry, Serica, Share (finance), EU

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into securities purchase agreements with new and existing investors and certain directors and officers in a registered direct offering of 31,746,030 shares of common stock (the Shares) at a purchase price of $3.15 per share, resulting in gross proceeds of approximately $100 million, before deducting placement agents fees and other estimated offering expenses.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into securities purchase agreements with new and existing investors and certain directors and officers in a registered direct offering of 31,746,030 shares of common stock (the Shares) at a purchase price of $3.15 per share, resulting in gross proceeds of approximately $100 million, before deducting placement agents fees and other estimated offering expenses.
  • The offering is expected to close on July 5, 2022, subject to customary closing conditions.
  • J.P. Morgan Securities LLC is acting as the exclusive placement agent for the offering.
  • Any such forward-looking statements represent Seres managements estimates as of the date of this press release.

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Retrieved on: 
Tuesday, June 7, 2022
Health, FDA, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Bloodstream infections, Breakthrough therapy, Adult, Company, Ulcerative colitis, Research, Safety, Food, AGAF, Spore, Security (finance), U.S. Securities and Exchange Commission, Nasdaq, Therapy, Graft-versus-host disease, FDA, ID, Growth, Hematopoietic stem cell transplantation, Patient, The New England Journal of Medicine, Private Securities Litigation Reform Act, Risk, Review, Variometer, PCR, COVID-19, BLA, Diagnosis, FACG, SEC, MD, Population, Firmicutes, CDI, Tissue, Orphan drug, Yale School of Medicine, Recurrence, David Berry (inventor), NEJM, Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI).

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI).
  • The ECOSPOR IV data confirm the well-tolerated safety profile and clinical benefit observed in the prior ECOSPOR III study, said Eric Shaff, President and Chief Executive Officer at Seres.
  • These results, along with the start of the rolling BLA submission, significantly advance our ability to deliver what may be the first FDA-approved microbiome therapeutic.
  • Safety data across both ECOSPOR IV and ECOSPOR III are expected to fulfill this requirement and complete Seres Phase 3 program for SER-109.

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Retrieved on: 
Sunday, May 22, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Risk, Company, Organic acid, Doctor of Philosophy, CDI, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Food, U.S. Securities and Exchange Commission, DDW, Nasdaq, Ulcerative colitis, Variometer, Biologics license application, Infection, Patient, Spore, Bacteria, Vancomycin, File, Therapy, The New England Journal of Medicine, COVID-19, BLA, Graft-versus-host disease, Orphan drug, Research, FDA, Breakthrough therapy, Recurrence, Bloodstream infections, David Berry (inventor), Safety, Fatty acid, Hematopoietic stem cell transplantation, SEC, Growth, Security (finance), Tissue, Dietary supplement, Pharmaceutical industry, Antibiotics, Firmicutes, Serica

These data were shared in oral and poster presentations at the 2022 Digestive Disease Week (DDW) Annual Meeting.

Key Points: 
  • These data were shared in oral and poster presentations at the 2022 Digestive Disease Week (DDW) Annual Meeting.
  • The pattern of results was the same regardless of which antibiotic participants received, vancomycin or fidaxomicin.
  • The SER-109 program is being advanced to prevent the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Retrieved on: 
Tuesday, May 10, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, COVID-19, Treatment, U.S. Securities and Exchange Commission, Graft-versus-host disease, Private Securities Litigation Reform Act, Clostridioides difficile infection, Ulcerative colitis, Nasdaq, Gastrointestinal disease, User experience, Company, Food, Physician, Safety, Hematopoietic stem cell transplantation, Patient, BLA, Security (finance), Recurrence, FDA, DDW, Variometer, National Digestive Diseases Information Clearinghouse, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CDI, Firmicutes, Orphan drug, Tissue, Breakthrough therapy, Biologics license application, David Berry (inventor), Bloodstream infections, SEC, Spore, Research, Growth, Annual general meeting, Risk, Pharmaceutical industry, Serica

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week (DDW) Annual Meeting, which is taking place May 21-24, 2022.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week (DDW) Annual Meeting, which is taking place May 21-24, 2022.
  • SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI).
  • With an oral and poster presentation, Seres will present data on how SER-109 restores the functionality of the microbiome in a rapid and durable manner, which further supports the potential of microbiome therapeutics.
  • Seres expects to finalize a Biologics License Application (BLA) submission for SER-109 with the U.S. Food and Drug Administration (FDA) in mid-2022.

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Other Health, Health, Stem Cells, Pharmaceutical, COVID-19, U.S. Securities and Exchange Commission, Graft-versus-host disease, Investment, David Berry (inventor), Private Securities Litigation Reform Act, University, Ulcerative colitis, File, Nasdaq, Company, Food, Safety, Research, Hematopoietic stem cell transplantation, Patient, BLA, Security (finance), Trial of the century, The New England Journal of Medicine, Clostridioides difficile infection, Infection, Program, FDA, Annual report, NEJM, Therapy, Chicago (franchise), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Incidence, CDI, Variometer, Tissue, Adult, Death, Medical Affairs Bureau, Disease, Bloodstream infections, SEC, Gastrointestinal tract, Growth, Memorial Sloan Kettering Cancer Center, Recurrence, Antibiotics, Pharmaceutical industry, Serica, UC

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates.
  • Seres continues to execute pre-commercialization activities in collaboration with Aimmune Therapeutics, including market education and data dissemination to the medical community.
  • Seres ended the first quarter of 2022 with approximately $248.0 million in cash, cash equivalents and investments as compared with $291.2 million at the end of 2021.
  • To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international) and reference the Seres Therapeutics conference call.

Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022

Retrieved on: 
Thursday, April 28, 2022
Science, Stem Cells, Biotechnology, Research, Health, FDA, Infectious Diseases, Clinical Trials, Patient, Hematopoietic stem cell transplantation, Nasdaq, FDA, Therapy, Tissue, Bloodstream infections, Company, Graft-versus-host disease, Research, Ulcerative colitis, NASDAQ, Recurrence, David Berry (inventor), Pharmaceutical industry, Serica

(NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m.

Key Points: 
  • (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m.
  • ET to discuss first quarter 2022 results and provide a general business update.
  • To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international) and request to be joined to the Seres Therapeutics call.
  • To join the live webcast, please visit the Investors and Media section of the Seres website at www.serestherapeutics.com .

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Retrieved on: 
Friday, March 18, 2022
Biotechnology, Infectious Diseases, Health, Stem Cells, Clinical Trials, Memorial Sloan Kettering Cancer Center, Private Securities Litigation Reform Act, Risk, Therapy, Recurrence, Colon, Extrapyramidal system, Population, CET, EBMT, Hematopoietic stem cell transplantation, Graft-versus-host disease, Chicago (franchise), Death, Growth, Adult, David Berry (inventor), Mouse, Bloodstream infections, HSCT, SEC, Doctor of Philosophy, Program, Ulcerative colitis, U.S. Securities and Exchange Commission, Tissue, Immunodeficiency, Security (finance), Safety, Clinical and Translational Science, Annual general meeting, Inflammation, Vancomycin, Nasdaq, COVID-19, Trial of the century, Gastrointestinal tract, Infection, Annual report, FDA, University, Patient, Vaccine, Pharmaceutical industry, Serica, SER-155, Seres Therapeutics, SER-155, SERES THERAPEUTICS

Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut.

Key Points: 
  • Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut.
  • In cultured human cells designed to mimic the lining of the intestines, SER-155 protected the barrier between the colon and invading pathogens from inflammatory damage.
  • Together, these platforms allow the researchers to pinpoint the potential immunomodulatory effects of gut microbes introduced by SER-155.
  • The SER-109 program is being advanced to reduce the recurrence of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic.